PHiD-CV vaccine: all 34 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-dose Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy InfantsCompletedNCT02447432Phase 3Results posted
• Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and ToddlersCompletedNCT02097472Phase 1/2Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine (Synflorix™) When Administered to Children Who Are at an Increased Risk of Pneumococcal InfectionCompletedNCT01746108Phase 3Results posted
• Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™CompletedNCT01641133Phase 3Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster DoseCompletedNCT01171989Phase 2Results posted
• Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in NigeriaCompletedNCT01153893Phase 3Results posted
• Primary Vaccination Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in VietnamCompletedNCT01153841Phase 3Results posted
• Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster DoseCompletedNCT01119625Phase 3Results posted
• Booster and Catch-up Vaccination With Vaccine GSK1024850ACompletedNCT01030822Phase 3Results posted
• Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A in Healthy Japanese ChildrenCompletedNCT01027845Phase 3Results posted
• Safety & Immunogenicity of Pneumococcal Vaccine 2189242A in Children Aged 12-23 Months at the Time of First VaccinationCompletedNCT00985751Phase 2Results posted
• Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in MaliCompletedNCT00985465Phase 3Results posted
• Long-term Follow-up Study of Children Previously Primed With GSK Pneumococcal Vaccine (GSK1024850A) and of Unprimed ChildrenCompletedNCT00950833Phase 3Results posted
• Booster Vaccination Study With a Pneumococcal Vaccine in Children Primed With the Same VaccineCompletedNCT00911144Phase 3Results posted
• Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive DiseaseCompletedNCT00861380Phase 3Results posted
• Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.CompletedNCT00829010Phase 3Results posted
• Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of AgeCompletedNCT00814710Phase 3Results posted
• Vaccination Course in Primed Children and Age-matched Unprimed Children With Pneumococcal Vaccine GSK1024850ACompletedNCT00792909Phase 3Results posted
• Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual AdministrationCompletedNCT00758264Phase 3Results posted
• Primary Vaccination Course in Children Receiving Pneumococcal Conjugate Vaccine GSK 1024850A or Prevenar™ and Hiberix™CompletedNCT00680914Phase 3Results posted
• Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/HibCompletedNCT00652951Phase 3Results posted
• Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate VaccineCompletedNCT00624819Phase 3Results posted
• Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same VaccinesCompletedNCT00547248Phase 3Results posted
• Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 8 Weeks of AgeCompletedNCT00533507Phase 3Results posted
• Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850ACompletedNCT00496015Phase 3Results posted
• Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of AgeCompletedNCT00489554Phase 3Results posted
• COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate VaccineCompletedNCT00466947Phase 3Results posted
• Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same VaccinesCompletedNCT00463437Phase 3Results posted
• Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.CompletedNCT00370396Phase 3Results posted
• Evaluation of PCV Schedules in a Naive Population in VietnamCompletedNCT02961231Phase 4
• Assessment of Novel Pneumococcal Conjugate Vaccination Scheduled in UK InfantsWithdrawnNCT02918708Phase 4
• Using Pneumococcal Vaccines in Combination for Maximum Protection From Ear and Lung Infections in First 3 Years of LifeCompletedNCT01735084Phase 4
• Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean ChildrenStatus unknownNCT01619462Phase 3
• PCV10 Reactogenicity and Immunogenicity Study - MalindiStatus unknownNCT01028326Phase 4

← PHiD-CV vaccine overview